Article ID Journal Published Year Pages File Type
9313141 Urology 2005 5 Pages PDF
Abstract
Prostate cancer traditionally was managed by monotherapy, and treatment was almost exclusively provided by the urologic surgeon. As ongoing clinical trials in advanced disease identify novel agents or combination therapies with good tolerability and potential survival benefits, multidisciplinary management may offer optimal care for men with high-risk prostate cancer, as it does for women with breast cancer. Patients with high-risk recurrent or metastatic disease should be informed of clinical trials for which they may be eligible.
Related Topics
Health Sciences Medicine and Dentistry Nephrology
Authors
, ,